Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - Head and neck cancer, excl. thyroid

859O - Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study

Date

20 Sep 2021

Session

Proffered Paper session - Head and neck cancer, excl. thyroid

Presenters

Wang-Zhong Li

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

W. Li1, Y. Xiang1, H. Hu2, S. Lv1, G. Liu1, H. Liang1, W. Xia1

Author affiliations

  • 1 Department Of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN
  • 2 Department Of Radiation Oncology, The First People's Hospital of Foshan, 528000 - Foshan/CN
More

Resources

Login to access the resources on OncologyPRO.

Abstract 859O

Background

Additional nonanatomic prognostic factors beyond TNM categories supplement evidence-based TNM classifications. We aimed to refine TNM staging groups for Epstein-Barr virus (EBV)-related nasopharyngeal carcinoma (NPC) by incorporating the EBV DNA status.

Methods

This multicenter retrospective cohort comprised 2,354 patients with nonmetastatic NPC treated with radiotherapy with or without chemotherapy between January 2008 and December 2016. Progression-free survival (PFS) and overall survival (OS) according to EBV DNA status and the 8th edition TNM staging system were compared. Recursive partitioning analysis (RPA) combined with supervised clustering was applied to derive prognostic groupings. A refined RPA stage was developed, validated, and compared with existing staging schemes.

Results

Pretreatment EBV DNA status was an independent prognostic factor. Lower survival probability by higher TNM stage was evident in EBV DNA (+) patients but not in those with EBV DNA (-) disease. Integrating EBV DNA status and TNM stage, the RPA stage divided nonmetastatic NPC into RPA-I (T1-3N0 or EBV DNA [-] T1-3N1), RPA-II (EBV DNA [+] T1-3N1-2 or EBV DNA [-] T1-3N2-3/T4N0-3), and RPA-III (EBV DNA [+] T4N0-3/T1-3N3) with distinctly different prognosis. The RPA stage outperformed the current TNM stage and two reported RPA staging schemes. These results were internally and externally validated. The new staging system identified approximately two-fold low-risk patients that might not benefit from chemotherapy than the current TNM staging system.

Conclusions

We developed and validated an RPA-based staging system for EBV-related NPC. This staging system may facilitate prognostic stratification and clinical trial designs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Natural Science Foundation of China; Guangdong Medical Research Foundation; Young Teacher Training Project of Sun Yat-sen University.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.